Greenwood Capital Associates LLC Sells 40 Shares of Danaher Co. (NYSE:DHR)

Greenwood Capital Associates LLC cut its stake in Danaher Co. (NYSE:DHR) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,183 shares of the conglomerate’s stock after selling 40 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Danaher were worth $968,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Cape Investment Advisory Inc. acquired a new stake in Danaher during the fourth quarter worth approximately $25,000. BKM Wealth Management LLC bought a new stake in Danaher in the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher in the 4th quarter valued at $29,000. Rakuten Securities Inc. bought a new position in Danaher during the 4th quarter worth $36,000. Finally, Financial Connections Group Inc. bought a new position in Danaher during the 4th quarter worth $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their price target for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Barclays raised their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. Bank of America raised their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Finally, Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $269.29.

Danaher Price Performance

Shares of DHR traded down $0.16 during mid-day trading on Friday, reaching $254.85. The company had a trading volume of 3,097,194 shares, compared to its average volume of 2,930,997. The company has a market capitalization of $188.76 billion, a price-to-earnings ratio of 43.19, a P/E/G ratio of 3.90 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company’s 50 day simple moving average is $253.48 and its 200 day simple moving average is $244.46. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the business posted $2.36 earnings per share. Analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. Danaher’s payout ratio is presently 18.31%.

Insider Activity

In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,783 shares of company stock valued at $37,536,717. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.